Drug Landscape ›
INTERFERON GAMMA-1A ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 20
Most-reported reactions
Abdominal Distension — 2 reports (10%) Abdominal Pain — 2 reports (10%) Clostridium Difficile Colitis — 2 reports (10%) Dehydration — 2 reports (10%) Diarrhoea — 2 reports (10%) Hypotension — 2 reports (10%) Nausea — 2 reports (10%) Pseudomembranous Colitis — 2 reports (10%) Pyrexia — 2 reports (10%) Tachycardia — 2 reports (10%)
Source database →
INTERFERON GAMMA-1A in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is INTERFERON GAMMA-1A approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for INTERFERON GAMMA-1A in United States?
Marketing authorisation holder not available in our data.